Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-3994 in heart failure with preserved ejection fraction
NCT04318145Phase 2Terminated
- Sponsor
- Palatin Technologies, Inc.
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PL-3994 in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Palatin Technologies, Inc. Primary endpoints: Part A: Dose Ascension and Optimization at 1 day and Coronary Sinus cGMP Levels at 1 day. Started Nov 2020; status: terminated.
02
Drugs
PL-3994
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04318145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318145.